Source comparison
BPC-157 Help Chronic Fatigue Research: Comparison of Intervention Mechanisms
BPC-157 peptide Mitochondrial biogenesis, anti-inflammatory cytokine modulation, nitric oxide pathway regulation 4–6 weeks for sustained benefit Animal studies strong; human trials absent Mitochondrial dysfunction, inflammation-driven fatigue Mechanistically s
This comparison does not assign a generated winner or score.
- BPC-157 peptide
- Mitochondrial biogenesis, anti-inflammatory cytokine modulation, nitric oxide pathway regulation
- 4–6 weeks for sustained benefit
- Animal studies strong; human trials absent
- Mitochondrial dysfunction, inflammation-driven fatigue
- Mechanistically sound but lacks Phase III human data. Best suited for cases unresponsive to conventional treatment
- Stimulant medications (methylphenidate, amphetamines)
- Central nervous system dopamine and norepinephrine reuptake inhibition
- Immediate (within 30–60 minutes)
- High. Multiple controlled trials
- Neurological fatigue, attention deficits
- Addresses symptom, not underlying pathology; tolerance and dependence risk
- Coenzyme Q10 (CoQ10)
- Mitochondrial electron transport chain cofactor
- 6–8 weeks
- Moderate. Mixed results in CFS trials
- Mitochondrial fatigue
- Effective when CoQ10 deficiency is present; limited benefit otherwise
- Modafinil (Provigil)
- Wakefulness-promoting agent via orexin and histamine pathways
- 1–2 hours
- Moderate. FDA-approved for narcolepsy, used off-label for CFS
- Central fatigue, excessive daytime sleepiness
- Does not restore cellular energy; masks fatigue perception
- Anti-inflammatory protocols (low-dose naltrexone, omega-3s)
- Cytokine reduction, microglial modulation
- 3–6 weeks
- Moderate. Some controlled trials show benefit
- Inflammation-driven fatigue
- Addresses one pathway; often combined with other interventions